1092407-76-5

Upstream product

• 1035229-33-4 5-(benzyloxy)-8-(2-chloroacetyl)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 1035229-32-3 8-acetyl-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one 
• 871101-87-0 1‐(3‐amino‐4‐(benzyloxy)‐2‐hydroxyphenyl)ethanone 
• 1092407-75-4 5-benzyloxy-8-[(R)-1-(tert-butyl-dimethyl-silanyloxy)-2-chloro-ethyl]-4H-benzo[1,4]oxazin-3-one 
• 601-89-8 2-nitroresorcinol 
• 3163-15-3 2-aminoresorcinol 
• 100-39-0 benzyl bromide 
• 177210-33-2 5-hydroxy-2H-benzo[b][1,4]oxazin-3(4H)-one 

Downstream Products

• 1179336-41-4 (R)-8-(2-azido-1-hydroxyethyl)-5-(benzyloxy)-2H-benzo[b][1,4]oxazin-3(4H)-one 

Relevant academic research and scientific papers

Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists

Aiming to discover dual-acting β2 adrenergic/dopamine D2 receptor ligands, a structure-guided approach for the evolution of GPCR agonists that address multiple targets was elaborated. Starting from GPCR crystal structures, we describ

BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED

The present invention relates to compounds of formula (I) having muscarinic M3 receptor and β-adrenergic receptor modulating activity; wherein R1, R2, R3 and X are as defined herein.